Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $11.16, gaining 26.1% over the past four weeks, ...

Day One Biopharmaceuticals (DAWN) enjoyed a strong third quarter in 2024, significantly beating top-and-bottom-line expectations driven by robust demand for cancer therapy OJEMDA. The company raised a ...

Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps ...

Since they bottomed in October 2022, the main stock indices have skyrocketed, The S&P 500 recording back-to-back gains of over 20% in 2023-2024, and the tech/growth-oriented Nasdaq-100 has performed ...

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands ...

Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 10.7% over the past four weeks to close the last trading session at $15.15, but there could still be a solid upside left in the stock if ...